This instance advises expanding immunization against CVIV-19 by the Pfizer-Biontech vaccine to children “at risk of serious forms due to comorbidities, regardless of age” and “living in the entourage Vulnerable adults “.
Le Monde with AFP
Vaccines against COVID-19 should not be given to all children but some of them should benefit from, estimated, Wednesday, November 17, the National Academy of Medicine, waiting for additional to confirm the good tolerance of the vaccine in children.
This instance, supposed to bring the consensus of medical knowledge, precise in a statement:
“The National Academy of Medicine recommends expanding immunization against [the] Covid-19 by the [Pfizer-Biontech] vaccine to children at risk of serious forms due to comorbidities, regardless of age , as well as other children living in their family and school environment. “
The Academy, whose opinions are only advisory, also advises to vaccinate “children living in the entourage of vulnerable adults, especially immunocompromissions and people with chronic diseases”.
This position comes after several days of controversy in France on the desirability of extending vaccination against Cvid-19 to children aged 5 to 11, as already done by the United States and Israel. Only more than 12 years can currently be vaccinated against COVID-19 in France.
Cardiac inflammations and very rare side effects
The subject is delicate because the individual benefits are a priori very limited for children: the serious forms of COVID-19 and, even more so, the deaths are very rare at home. But the Pfizer-Biontech and Moderna vaccines can punctually cause heart inflammation, very rare side effects but to work with the debatable profit of the smaller vaccine.
However, the arguments for the vaccination of children also relate to its collective dimension. It would aim to prevent the virus from circulating among them and therefore, subsequently, within the rest of the population.
The European health authorities are examining the question after receiving positive Pfizer and then Moderna data. These laboratories testify to the lack of serious effects but on a sample of a big thousand children, a priori insufficient to detect very rare but severe consequences.
A decision “at the beginning of the beginning of year 2022 “?
“If a decision must be made,” it could be “at the beginning of the year 2022,” said Jean-François DELFRISY, President of the Scientific Council, Wednesday on France inter .
In this context, several French pediatric companies and infectiology have revived the debate at the beginning of the week by expressing their skepticism on the vaccination of children. These bodies, including the French-language infectious pathology society, have thus estimated:
“The emergency in the vaccination of children 5-11 does not appear for the moment as evident in France.”
This position has reversed the indignation of supporters of childish vaccination. The Association Militant School and Families forgotten, fiercely opposed to “natural immunity by illness”, denounces a “betrayal” of children and calls for a “profit risk of vaccine” analysis for children.
